Showing 1911-1920 of 2314 results for "".
- Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defect (PCED)https://modernod.com/news/amber-ophthalmics-announces-positive-topline-phase-2-data-evaluating-nexagon-for-the-treatment-of-persistent-corneal-epithelial-defect-pced/2481332/Amber Ophthalmics announced positive topline results from the phase 2 randomized, double-masked, vehicle-controlled clinical trial (EXPEDE) evaluating two topically administered concentrations of Nexagon (lufepirsen ophthalmic gel) for the treatment of persistent corneal epithelial defect (P
- Elios Vision Announces Registration of Elios in the United Kingdomhttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-the-united-kingdom/2481318/Elios, a technology used to treat glaucoma at the same time as cataract surgery, is now registered for use in the United Kingdom, according to Elios Vision. The Elios does not require an implant and is designed to provide long-lasting results that may free patients and th
- Orasis Pharmaceuticals Submits NDA for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopiahttps://modernod.com/news/orasis-pharmaceuticals-submits-nda-for-investigational-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia/2481315/Orasis Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%). "This NDA submission is a significant milestone for Orasis as we advance CSF-1 towards commercialization and
- Elios Vision Announces Registration of Elios in Francehttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-france/2481304/Elios Vision announced that its Elios technology, which is used to treat glaucoma at the same time as cataract surgery, is now registered in France. Elios does not require an implant and is designed to provide long-lasting results that may free patients from drop therapy.
- Eversight and the Department of Health–Abu Dhabi Partner to Establish UAE’s First Eye and Tissue Bankhttps://modernod.com/news/eversight-and-the-department-of-health-abu-dhabi-partner-to-establish-uaes-first-eye-and-tissue-bank/2481291/Global nonprofit eye bank Eversight and the Department of Health – Abu Dhabi (DoH) are partnering to establish the first eye and tissue bank in the United Arab Emirates (UAE). The
- Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue Hydration Boost Contact Lens Rehydrating Dropshttps://modernod.com/news/bausch-lomb-receives-510k-clearance-from-fda-for-biotrue-hydration-boost-contact-lens-rehydrating-drops/2481290/Bausch + Lomb announced that it has received 510(k) clearance from the FDA for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free multi-dose rehydrating drop for use with soft and rigid gas permeable contact lenses. “We ar
- Lumibird Medical Launches Tango Reflex Neo YAG/SLT Laserhttps://modernod.com/news/lumibird-medical-launches-tango-reflex-neo-yagslt-laser/2481281/Lumibird Medical announced the launch of their next generation YAG/SLT laser, the Tango Reflex Neo, by Ellex. A fully integrated Q-switched Nd:YAG and frequency doubled Nd:YAG laser for anterior-segment YAG and glaucoma indications, Tango Reflex Neo features second-genera
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care-1/2481275/Nanodropper has launched its 2022 Give the Gift of Vision program, an effort to donate 1,000 Nanodropper Adaptors to at-need patients in the United States and its global nonprofit partners, aiming to deliver better access to vision-saving care in low resource settings in Africa, Haiti, and e
- Improved PC-IOL Technology is Key to Recent and Future Premium Cataract Surgery Growthhttps://modernod.com/news/improved-pc-iol-technology-is-key-to-recent-and-future-premium-cataract-surgery-growth/2481273/Presbyopia-correcting IOL technology improvements have led to almost a doubling of global units over the past 5 years and will be critical to driving future growth over the next 5 years, according to a Market Scope report. In 2022, PC-IOLs will represent nearly 55 percent of premi
- MediPrint Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Assethttps://modernod.com/news/mediprint-ophthalmics-announces-it-has-initiated-its-sight-2-phase-2b-clinical-study-for-its-lead-asset/2481231/MediPrint Ophthalmics announced it has initiated its SIGHT-2 dose-finding phase 2b study for its proprietary drug-eluting contact lens for glaucoma. This is the second study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating